Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B

Journal of Medical Virology

Volumn 81, Issue 3, 2009, Pages 417-424

  Choong, Keun Cha ^a   Hyeok, Choon Kwon ^b   Jae, Youn Cheong ^b   Sung, Won Cho ^b   Sun, Pyo Hong ^c   Kim, Soo Ok ^c   Wang, Don Yoo ^c  

^a CHA University   (South Korea)

^b Ajou University School of Medicine   (South Korea)

^c GeneMatrix Inc   (South Korea)

Author keywords

Antiviral resistance; Hepatitis B virus; Mutation; Reverse transcriptase

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; DNA SEQUENCE; DRUG EFFECT; GENETICS; HEPATITIS B VIRUS; MIDDLE AGED; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SERUM; VIROLOGY;

HEPATITIS B VIRUS;

ADENINE; ADULT; ANTIVIRAL AGENTS; DNA MUTATIONAL ANALYSIS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION, MISSENSE; PHOSPHONIC ACIDS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SEQUENCE ANALYSIS, DNA; SERUM; VIRAL LOAD;

EID: 60049099815     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21402     Document Type: Article

References (31)

1. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27:1670-1677.
2. Anon. 2003. Proceedings of the European Association for the Study of the Liver (EASL) International Consensus Conference on Hepatitis B. September 14-16, 2002. Geneva, Switzerland. J Hepatol 39:S1-S235.
3. Bartholomeusz A, Schaefer S. 2004. Hepatitis B virus genotypes: Comparison of genotyping methods. Rev Med Virol 14:3-16.
4. Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P, Gibbs CS, Brosgart C, Fry J, Namini H, Katlama C, Poynard T. 2001. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: An open-label pilot study. Lancet 358:718-723.
5. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. 2006. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295:65-73.
6. Conjeevaram HS, Lok AS. 2003. Management of chronic hepatitis B. J Hepatol 38:S90-S103.
7. Delaney WEt, Locarnini S, Shaw T. 2001. Resistance of hepatitis B virus to antiviral drugs: Current aspects and directions for future investigation. Antivir Chem Chemother 12:1-35.
8. Delaney WEt, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, Miller MD, Xiong S. 2003. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 77:11833-11841.
9. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW,Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA. 1999. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341:1256-1263.
10. Enomoto M, Tamori A, Kohmoto MT, Morikawa H, Habu D, Sakaguchi H, Takeda T, Seki S, Kawada N, Shiomi S, Nishiguchi S. 2007. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: Analyses of the polymerase gene and full-length sequences. J Med Virol 79:1664-1670.
11. Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, Hussain M, Lok AS. 2006. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 44:283-290.
12. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Arterburn S, Xiong S, Currie G, Brosgart CL. 2005. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 352:2673-2681.
13. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. 2006. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130:678-686.
14. Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V. 2004. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 9:353-363.
15. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. 1998. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 339:61-68.
16. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L. 2003. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 36:687-696.
17. Liaw YF. 2007. Rescue therapy for lamivudine-resistant chronic hepatitis B: When and how? Hepatology 45:266-268.
18. Liaw YF, Chien RN, Yeh CT. 2004. No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antivir Ther 9:257-262.
19. Lok AS. 2002. Chronic hepatitis B. N Engl J Med 346:1682-1683.
20. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M. 2003. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125:1714-1722.
21. Lok AS, McMahon BJ. 2004. Chronic hepatitis B: Update of recommendations. Hepatology 39:857-861.
22. Lok AS, McMahon BJ. 2007. Chronic hepatitis B. Hepatology 45:507-539.
23. Ogata N, Fujii K, Takigawa S, Nomoto M, Ichida T, Asakura H. 1999. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B. J Med Virol 59:270-276.
24. Ono Y, Onda H, Sasada R, Igarashi K, Sugino Y, Nishioka K. 1983. The complete nucelotide sequences of the cloned hepatitis B virus DNA: subtype adr and adw. Nucleic Acids Res 11:1747-1757.
25. Shaw T, Bowden S, Locarnini S. 2004. Rescue therapy for drug resistant hepatitis B: Another argument for combination chemotherapy? Gastroenterology 126:343-347.
26. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF. 2001. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33:751-757.
27. Suzuki F, Kumada H, Nakamura H. 2006. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy. J Med Virol 78:1025-1034.
28. Warner N, Locarnini S, Kuiper M, Bartholomeusz A, Ayres A, Yuen L, Shaw T. 2007. The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob Agents Chemother 51:2285-2292.
29. Westland CE, Yang H, Delaney WEt, Wulfsohn M, Lama N, Gibbs CS, Miller MD, Fry J, Brosgart CL, Schiff ER, Xiong S. 2005. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients. J Viral Hepat 12:67-73.
30. Wong VW, Chan HL, Wong ML, Tam JS, Leung NW. 2004. Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants. Aliment Pharmacol Ther 19:323-329.
31. Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS. 1998. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 28:1669-1673.